Forte Biosciences Inc
FBRX · NASDAQ · USD · Market cap $1.6B · 22 employees
Forte Biosciences, Inc.
FAIL · Does not pass the screenPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price76.99 USD at the 19 Nov 2026 close
- Our value readFair vs our fair value, as of 19 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed19 Nov 2026 (2 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $61.00 to $77.00, base estimate $77.00 (screen dated 2026-11-19).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Forte Biosciences Inc holds its Accumulation at $76.99. Elevated stress, defensive posture warranted, held for 11 days.
| Phase | Accumulation |
| Quantitative state | Elevated stress, defensive posture warranted, held for 11 days |
| Price at the screen | $76.99 |
| Valuation | N/A trailing · -18.89 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 2.65 |
Five Screens: FBRX's Results
FAIL. Accounts receivable
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | Excluded | Below 33% | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Pass |
| Receivables | 93.95% | Below 49% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Forte Biosciences's business is fine, but its receivables are about 94% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when FBRX's ethical verdict changes
Today FBRX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair to fair value, as of 19 Nov 2026: it trades at roughly a 0% discount to our $77.00 fair value, none competitive moat.
USD, 2026-11-19 screen. A 0.0% under base.
Street: 4 covering, consensus Buy. Average target +0%.
Clinical stage biotech with no revenue or moat
Picture a lab racing to turn one antibody into a treatment for several autoimmune diseases, yet still years from any sales. Forte Biosciences sits in exactly that spot. The shares trade below our fair value estimate, analysts like the story, and the ethical screen raises no flags, yet the opportunity rating stays at none because the business has no moat, no profits, and negative returns on equity of 188 percent.
Forward earnings sit at a negative 11.8 times while the profit margin remains zero. The lead candidate, FB-102, targets CD122 but has yet to prove itself in large trials. Without recurring revenue or pricing power, any upside rests on binary clinical results rather than steady cash flow.
Risk sits around the usual biotech trap of repeated capital raises and trial setbacks that can wipe out value quickly. Even a clean ethical pass cannot offset the absence of a durable business. Analysis, not advice.
| Forward P/E | -18.9x |
| EPS, trailing | -4.57 |
| EPS, forward | -4.08 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -62.3%not currently earning a positive return on equity |
| FCF yield | -2.53% |
| Current ratio | 10.01comfortably covers its short-term bills |
| Beta | 2.65much more volatile than the market |
| Short interest, float | 0.08% |
| 52-week range | 10.11 - 77.20 |
| Moat | NONE |
| Market cap | $1.6B |
| Employees | 22 |
FBRX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
Earnings landed in this window.
Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition Simply Wall St. · 27 Aug 2026
- Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition Yahoo Finance · 27 Aug 2026
- Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences Insider Monkey · 11 Aug 2026
- Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences Yahoo Finance · 11 Aug 2026
- argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition Simply Wall St. · 10 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $26.00 | -35.5% | · | $645 | -35.5% |
| 2 months | $35.09 | -52.2% | · | $478 | -52.2% |
| 3 months | $27.12 | -38.2% | · | $618 | -38.2% |
| 6 months | $22.65 | -26.0% | · | $740 | -26.0% |
| 1 year | $12.25 | +36.9% | · | $1,369 | +36.9% |
| 2 years | $13.75 | +22.0% | · | $1,220 | +22.0% |
| 3 years | $24.80 | -32.4% | · | $676 | -32.4% |
| 5 years | $1,020.50 | -98.4% | · | $16 | -98.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever FBRX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.